Dr Reddy's Laboratories has partnered with FUJIFILM Corporation through FUJIFILM Toyama Chemical (FUJIFILM) and Global Response Aid (GRA) for the development, manufacture and sales of Avigan Tablets (generic name: favipiravir), a potential treatment of COVID-19.
Under the tripartite agreement signed on June 30, 2020, FUJIFILM grants Dr. Reddy’s the exclusive rights of manufacturing and also grants both Dr. Reddy’s and GRA the rights to develop, sell and distribute Avigan in all countries other than Japan, China and Russia. The company would have exclusive rights for development, selling and distribution of Avigan in India. Further, FUJIFILM would receive an upfront license fee and royalties on sales from Dr. Reddy’s and GRA. The FUJIFILM Group is currently conducting a clinical study on Avigan targeting COVID-19 patients in Japan and the US, and is working to increase the drug’s production by partnering with domestic and overseas companies. Dr. Reddy’s and GRA shall introduce the product in the market post all applicable approvals in the respective countries.
Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.